Literature DB >> 12618536

Pharmacokinetic drug interactions of morphine, codeine, and their derivatives: theory and clinical reality, part I.

Scott C Armstrong1, Kelly L Cozza.   

Abstract

Pharmacokinetic drug-drug interactions with morphine, hydromorphone, and oxymorphone are reviewed in this column. Morphine is a naturally occurring opiate that is metabolized chiefly through glucuronidation by uridine diphosphate glucuronosyl transferase (UGT) enzymes in the liver. These enzymes produce an active analgesic metabolite and a potentially toxic metabolite. In vivo drug-drug interaction studies with morphine are few, but they do suggest that inhibition or induction of UGT enzymes could alter morphine and its metabolite levels. These interactions could change analgesic efficacy. Hydromorphone and oxymorphone, close synthetic derivatives of morphine, are also metabolized primarily by UGT enzymes. Hydromorphone may have a toxic metabolite similar to morphine. In vivo drug-drug interaction studies with hydromorphone and oxymorphone have not been done, so it is difficult to make conclusions with these drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12618536     DOI: 10.1176/appi.psy.44.2.167

Source DB:  PubMed          Journal:  Psychosomatics        ISSN: 0033-3182            Impact factor:   2.386


  14 in total

Review 1.  Mini-series: II. clinical aspects. clinically relevant CYP450-mediated drug interactions in the ICU.

Authors:  Isabel Spriet; Wouter Meersseman; Jan de Hoon; Sandrina von Winckelmann; Alexander Wilmer; Ludo Willems
Journal:  Intensive Care Med       Date:  2009-01-09       Impact factor: 17.440

Review 2.  Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain.

Authors:  James E Frampton
Journal:  Drugs       Date:  2010-09-10       Impact factor: 9.546

3.  Effects of Oral Morphine on Dyspnea in Patients with Cancer: Response Rate, Predictive Factors, and Clinically Meaningful Change (CJLSG1101).

Authors:  Kosuke Takahashi; Masashi Kondo; Masahiko Ando; Akira Shiraki; Harunori Nakashima; Hisashi Wakayama; Kensuke Kataoka; Masashi Yamamoto; Yasuteru Sugino; Mitsunori Nishikawa; Kazuyoshi Imaizumi; Eiji Kojima; Atsushi Sumida; Yoshihiro Takeyama; Hiroshi Saito; Yoshinori Hasegawa
Journal:  Oncologist       Date:  2019-01-18

Review 4.  Biological pathways and genetic variables involved in pain.

Authors:  Qiuling Shi; Charles S Cleeland; Pål Klepstad; Christine Miaskowski; Nancy L Pedersen
Journal:  Qual Life Res       Date:  2010-09-15       Impact factor: 4.147

Review 5.  Efflux transporters- and cytochrome P-450-mediated interactions between drugs of abuse and antiretrovirals.

Authors:  Dhananjay Pal; Deep Kwatra; Mukul Minocha; Durga K Paturi; Balasubrahmanyam Budda; Ashim K Mitra
Journal:  Life Sci       Date:  2010-11-01       Impact factor: 5.037

Review 6.  Structural features of cytochromes P450 and ligands that affect drug metabolism as revealed by X-ray crystallography and NMR.

Authors:  Sean C Gay; Arthur G Roberts; James R Halpert
Journal:  Future Med Chem       Date:  2010-09       Impact factor: 3.808

Review 7.  Oxymorphone: a review.

Authors:  Eric Prommer
Journal:  Support Care Cancer       Date:  2005-11-30       Impact factor: 3.603

Review 8.  Pain treatment with opioids : achieving the minimal effective and the minimal interacting dose.

Authors:  Pierangelo Geppetti; Silvia Benemei
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

9.  Fatal and severe codeine intoxication in 3-year-old twins--interpretation of drug and metabolite concentrations.

Authors:  Nerea Ferreirós; Sebastian Dresen; Maren Hermanns-Clausen; Volker Auwaerter; Annette Thierauf; Christoph Müller; Roland Hentschel; Rainer Trittler; Gisela Skopp; Wolfgang Weinmann
Journal:  Int J Legal Med       Date:  2009-04-07       Impact factor: 2.686

Review 10.  MDR- and CYP3A4-mediated drug-drug interactions.

Authors:  Dhananjay Pal; Ashim K Mitra
Journal:  J Neuroimmune Pharmacol       Date:  2006-08-02       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.